Facebook Pixel

ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (audio)

GRACEcast Lung Cancer Audio
GRACEcast Lung Cancer Audio

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

GRACEcast Lung Cancer Audio
Not playing